205 related articles for article (PubMed ID: 28342027)
1. A comparative evaluation of Ac225 vs Bi213 as therapeutic radioisotopes for targeted alpha therapy for cancer.
Allen BJ
Australas Phys Eng Sci Med; 2017 Jun; 40(2):369-376. PubMed ID: 28342027
[TBL] [Abstract][Full Text] [Related]
2. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
[TBL] [Abstract][Full Text] [Related]
3. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
Kozempel J; Mokhodoeva O; Vlk M
Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
[TBL] [Abstract][Full Text] [Related]
4. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy with alpha-particle emitting radionuclides.
Zalutsky MR; Pozzi OR
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
[TBL] [Abstract][Full Text] [Related]
6. An Appendix of Radionuclides Used in Targeted Alpha Therapy.
Ferrier MG; Radchenko V
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S58-S65. PubMed ID: 31427258
[No Abstract] [Full Text] [Related]
7. Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.
Dhiman D; Vatsa R; Sood A
Nucl Med Commun; 2022 Sep; 43(9):970-977. PubMed ID: 35950353
[TBL] [Abstract][Full Text] [Related]
8. Development of Targeted Alpha Therapy from Bench to Bedside.
Morgenstern A; Bruchertseifer F
J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S18-S20. PubMed ID: 31405818
[TBL] [Abstract][Full Text] [Related]
9. An Overview of Targeted Alpha Therapy with
Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.
Radchenko V; Schaffer P; Knapp FFR
Curr Radiopharm; 2018; 11(3):154-155. PubMed ID: 30378473
[No Abstract] [Full Text] [Related]
11. Targeted alpha therapy with 213Bi.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2011 Oct; 4(4):295-305. PubMed ID: 22202152
[TBL] [Abstract][Full Text] [Related]
12. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Lee D; Li M; Bednarz B; Schultz MK
Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
[TBL] [Abstract][Full Text] [Related]
13. Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.
Thiele NA; Wilson JJ
Cancer Biother Radiopharm; 2018 Oct; 33(8):336-348. PubMed ID: 29889562
[TBL] [Abstract][Full Text] [Related]
14. Advancements in cancer therapy with alpha-emitters: a review.
Imam SK
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):271-8. PubMed ID: 11516878
[TBL] [Abstract][Full Text] [Related]
15. Actinium-225 in targeted alpha-particle therapeutic applications.
Scheinberg DA; McDevitt MR
Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
[TBL] [Abstract][Full Text] [Related]
16. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
17. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
[TBL] [Abstract][Full Text] [Related]
18. Cancer radioimmunotherapy with alpha-emitting nuclides.
Couturier O; Supiot S; Degraef-Mougin M; Faivre-Chauvet A; Carlier T; Chatal JF; Davodeau F; Cherel M
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):601-14. PubMed ID: 15841373
[TBL] [Abstract][Full Text] [Related]
19. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials.
Marcu L; Bezak E; Allen BJ
Crit Rev Oncol Hematol; 2018 Mar; 123():7-20. PubMed ID: 29482781
[TBL] [Abstract][Full Text] [Related]
20. Supply and Clinical Application of Actinium-225 and Bismuth-213.
Morgenstern A; Apostolidis C; Bruchertseifer F
Semin Nucl Med; 2020 Mar; 50(2):119-123. PubMed ID: 32172796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
